A phase II trial of docetaxel/prednisone in combination with sargramostim as treatment for hormone-refractory prostate cancer.

Trial Profile

A phase II trial of docetaxel/prednisone in combination with sargramostim as treatment for hormone-refractory prostate cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 May 2012

At a glance

  • Drugs Docetaxel; Prednisone; Sargramostim
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 Aug 2008 Planned end date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top